Cargando…

Comment on “Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”

Detalles Bibliográficos
Autor principal:	Qian, Xinye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health, Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431329/ https://www.ncbi.nlm.nih.gov/pubmed/37600880 http://dx.doi.org/10.1097/AS9.0000000000000254

Ejemplares similares

Response to: “Comment on Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”
por: Famularo, Simone, et al.
Publicado: (2023)

Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial
por: Chen, Jia-Hao, et al.
Publicado: (2020)

Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
por: Zhuang, Lei, et al.
Publicado: (2017)

Spontaneous rupture of hepatocellular carcinoma trans-arterial embolization or hepatectomy?
por: Feng, Qingbo, et al.
Publicado: (2022)

Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression
por: Matsuki, Ryota, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis
por: Hou, Yanli, et al.
Publicado: (2020)

Advanced nonmetastatic hepatocellular carcinoma: curative surgery may be an option
por: Leclerc, Julie, et al.
Publicado: (2022)

Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma
por: Lamarca, A, et al.
Publicado: (2012)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Is transarterial embolization plus two-stage hepatectomy the optimal strategy for the treatment of spontaneous rupture of hepatocellular carcinoma?
por: He, Tao, et al.
Publicado: (2023)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
por: Huang, Yun, et al.
Publicado: (2019)

A comment on ‘A morpho-molecular prognostic model for hepatocellular carcinoma'
por: Halil Sahin, I, et al.
Publicado: (2013)

Comment on “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis”
por: Tang, Xiao-Long, et al.
Publicado: (2022)

Radiochemotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer
por: Schäfer, C, et al.
Publicado: (2006)

Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study
por: He, Wei, et al.
Publicado: (2020)

Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Deng, Min, et al.
Publicado: (2023)

Comment on: “Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis”
por: Liu, Xiangyu, et al.
Publicado: (2022)

Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy
por: Shao, Mingyang, et al.
Publicado: (2023)

Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy
por: Dong, Wei, et al.
Publicado: (2021)

Comment on ‘Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'
por: Grizzi, F, et al.
Publicado: (2016)

Comment on ‘Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion’
por: Huo, Teh-Ia, et al.
Publicado: (2017)

Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Reply
por: Yim, Hyung Joon, et al.
Publicado: (2023)

Comment on Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy?: A Retrospective Multicentric Study
por: Xing, Jiali, et al.
Publicado: (2022)

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy
por: Wei, Meng-Chao, et al.
Publicado: (2022)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes
por: Xie, Yong, et al.
Publicado: (2021)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Response to: Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”
por: Yuan, Peng, et al.
Publicado: (2016)

Reply to: Comment on ‘Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'
por: Sideras, Kostandinos, et al.
Publicado: (2016)

Reply to ‘Comment on ‘Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion’ ’
por: Waked, Iman, et al.
Publicado: (2017)

Is laparoscopic hepatectomy superior to open hepatectomy for hepatocellular carcinoma?
por: Zhong, Jian-Hong, et al.
Publicado: (2017)

Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'
por: Cucchetti, Alessandro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_epitabdb2bimbmsni4q920vkm8